Foundation Sponsors

Ferring Pharmaceuticals

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Founded in 1950, privately-owned Ferring employs over 7,000 people worldwide. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within microbiome/gastroenterology and uro-oncology/urology. The company has emerged as a world leader with one of the largest peptide therapeutics portfolios in the industry. As part of its commitment to developing innovative products to treat diseases with high unmet medical need, Ferring invests heavily in its research infrastructure both in terms of people and technology. The company has operating subsidiaries in more than 50 countries and markets its products in over 100 countries.

Neurocrine Biosciences

Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson’s disease, endometriosis* and uterine fibroids*, as well as over a dozen mid- to late-stage clinical programs in multiple therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. (*in collaboration with AbbVie).

Novo Nordisk

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 41,700 people in 77 countries and markets its products in more than 165 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.

PolyPeptide

PolyPeptide is a publicly listed organization, traded on the Swiss stock exchange, which focuses on manufacturing proprietary and generic GMP-grade peptides and oligonucleotides for the pharmaceutical and biotechnological market. With more than 60 years of experience, PolyPeptide is committed to the highest quality of manufacturing for commercial peptide drug substances, GMP peptides in clinical trials, or small-scale pre-clinical custom syntheses.

As an organization, PolyPeptide has grown by selective acquisition of existing expertise, culminating in its position today as a leader in peptide manufacturing. With three manufacturing facilities in Europe, two facilities in the US , and one in Asia, PolyPeptide is a multinational company with about 1200 employees worldwide with a diversity which brings breadth and depth of knowledge, as well as unique experience to the organization.

PolyPeptide’s long-established core strength is in GMP manufacturing, and a broad range of services which supports peptide & peptide-like projects, including conjugation to non-peptide moieties, from bench scale through to commercialization. With continually increasing capacity for GMP manufacturing, PolyPeptide is uniquely placed to serve the needs of its customers at all stages of pharmaceutical peptide development with a proven track record in security of supply to its clients.

Zealand Pharma

Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) is a biotechnology company specialized in the discovery, design and development of peptide-based therapeutics. The company has a portfolio of medicines and product candidates under license collaborations with Sanofi and Boehringer Ingelheim and a proprietary pipeline of product candidates, which primarily target specialty diseases with significant unmet needs.
Zealand is the inventor of lixisenatide, a once-daily prandial GLP-1 analog for the treatment of type 2 diabetes, which is licensed to Sanofi and marketed globally outside the U.S. as Lyxumia® and in the U.S. as Adlyxin®. Sanofi has also developed iGlarLixi, a fixed-ratio combination of lixisenatide and Lantus® (insulin glargine) marketed in U.S. as Soliqua® and Europe as Suliqua®.
Zealand’s proprietary pipeline includes; glepaglutide*, a GLP-2 analog for the treatment of short bowel syndrome which will initiate Phase III studies in 1H18; dasiglucagon*, a glucagon analog in Phase III as a single-dose rescue therapy for severe hypoglycemia and in Phase II as a multiple-dose component in a dual-hormone artificial pancreas system; and other earlier stage clinical and preclinical peptide therapeutics. The company has approximately 130 employees and is based in Copenhagen, Denmark.
* Glepaglutide and dasiglucagon are proposed International Nonproprietary Names (pINNs)